We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Qrons Inc (QB) | USOTC:QRON | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.185475 | 0.156 | 0.2818 | 0.00 | 20:30:01 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2023
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
000-55800
(Commission File Number)
QRONS INC. |
(Exact name of registrant as specified in its charter) |
Wyoming |
| 81-3623646 |
(State or other jurisdiction of incorporation or organization) |
| (I.R.S. Employer Identification No.) |
| ||
28-10 Jackson Avenue #26N Long Island City, New York |
| 11101 |
(Address of principal executive offices) |
| (Zip Code) |
(212)-945-2080
(Registrant’s telephone number, including area code)
______________________________________________
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act: None
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
None |
| N/A |
| N/A |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated Filer | ☒ | Smaller reporting company | ☒ |
|
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 15, 2023 there were 13,439,789 shares of the registrant’s common stock outstanding.
QRONS INC.
TABLE OF CONTENTS
|
|
|
| Page |
|
|
|
|
|
| |
|
|
|
|
|
|
|
| 3 |
| ||
|
|
|
|
|
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
| 22 |
| |
|
|
|
|
|
|
|
| 27 |
| ||
|
|
|
|
|
|
|
| 27 |
| ||
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 28 |
| ||
|
|
|
|
|
|
|
| 29 |
| ||
|
|
|
|
|
|
|
|
| 30 |
|
| 2 |
| Table of Contents |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
QRONS INC.
CONDENSED BALANCE SHEETS
(Unaudited)
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 3 |
| Table of Contents |
QRONS INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
|
| For the Three Months Ended |
| |||||
|
| March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
|
|
|
|
|
|
| ||
Net sales |
| $ | - |
|
| $ | - |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development expenses |
|
| 6,820 |
|
|
| 8,932 |
|
Professional fees |
|
| 22,345 |
|
|
| 44,866 |
|
General and administrative expenses |
|
| 7,777 |
|
|
| 9,758 |
|
Total operating expenses |
|
| 36,942 |
|
|
| 63,556 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
| (36,942 | ) |
|
| (63,556 | ) |
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
Interest expense |
|
| (17,477 | ) |
|
| (34,617 | ) |
Change in derivative liabilities |
|
| (14,039 | ) |
|
| (165,955 | ) |
Total other income (expense) |
|
| (31,516 | ) |
|
| (200,572 | ) |
|
|
|
|
|
|
|
|
|
Net loss |
| $ | (68,458 | ) |
| $ | (264,128 | ) |
|
|
|
|
|
|
|
|
|
Net loss per common shares (basic and diluted) |
| $ | (0.01 | ) |
| $ | (0.02 | ) |
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
(basic and diluted) |
|
| 13,439,789 |
|
|
| 13,289,789 |
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 4 |
| Table of Contents |
QRONS INC.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
For the Three Months Ended March 31, 2023 and 2022
(Unaudited)
|
|
|
|
|
| Additional |
|
|
|
| Total |
| ||||||||||||||||
|
| Series A Preferred |
|
| Common Stock |
|
| Paid-in |
|
| Accumulated |
|
| Stockholders’ |
| |||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Deficit |
| |||||||
Balance, December 31, 2022 |
|
| 2,000 |
|
| $ | 2 |
|
|
| 13,439,789 |
|
| $ | 1,344 |
|
| $ | 8,254,316 |
|
| $ | (9,534,944 | ) |
| $ | (1,279,282 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (68,458 | ) |
|
| (68,458 | ) |
Balance, March 31, 2023 |
|
| 2,000 |
|
| $ | 2 |
|
|
| 13,439,789 |
|
| $ | 1,344 |
|
| $ | 8,254,316 |
|
| $ | (9,603,402 | ) |
| $ | (1,347,740 | ) |
|
| Series A Preferred |
|
| Common Stock |
|
| Additional Paid-in |
|
| Accumulated |
|
| Total Stockholders’ |
| |||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Deficit |
| |||||||
Balance, December 31, 2021 |
|
| 2,000 |
|
| $ | 2 |
|
|
| 13,289,789 |
|
| $ | 1,329 |
|
| $ | 7,697,351 |
|
| $ | (8,801,427 | ) |
| $ | (1,102,745 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for the period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (264,128 | ) |
|
| (264,128 | ) |
Balance, March 31, 2022 |
|
| 2,000 |
|
| $ | 2 |
|
|
| 13,289,789 |
|
| $ | 1,329 |
|
| $ | 7,697,351 |
|
| $ | (9,065,555 | ) |
| $ | (1,366,873 | ) |
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 5 |
| Table of Contents |
QRONS INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
|
| For the Three Months ended March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
Cash Flows From Operating Activities |
|
|
|
|
|
| ||
Net loss |
| $ | (68,458 | ) |
| $ | (264,128 | ) |
Adjustments to reconcile net loss to net cash used by operating activities: |
|
|
|
|
|
|
|
|
Accretion of debt discount |
|
| 11,377 |
|
|
| 29,291 |
|
Change in derivative liabilities |
|
| 14,039 |
|
|
| 165,955 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
(Increase) in prepaid expenses |
|
| - |
|
|
| (2,163 | ) |
Increase in accounts payable and accrued liabilities |
|
| 17,856 |
|
|
| 41,054 |
|
Increase in accounts payable and accrued liabilities - related party |
|
| 11,605 |
|
|
| 580 |
|
Net cash used by operating activities |
|
| (13,581 | ) |
|
| (29,411 | ) |
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities |
|
|
|
|
|
|
|
|
Net cash provided from (used by) investing activities |
|
| - |
|
|
| - |
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
Proceeds from related party advances |
|
| 15,000 |
|
|
| - |
|
Net cash provided from financing activities |
|
| 15,000 |
|
|
| - |
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
| 1,419 |
|
|
| (29,411 | ) |
|
|
|
|
|
|
|
|
|
Cash at beginning of year |
|
| 3,069 |
|
|
| 35,065 |
|
Cash at end of period |
| $ | 4,488 |
|
| $ | 5,654 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES |
|
|
|
|
|
|
|
|
Interest paid |
| $ | - |
|
| $ | - |
|
Income taxes paid |
| $ | - |
|
| $ | - |
|
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 6 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 1 – Description of Business and Basis of Presentation
Organization and Nature of Business:
Qrons Inc. (“Qrons” or the “Company”) was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. and changed its name to Qrons Inc., effective August 8, 2017.
The Company’s common stock was approved by the Financial Industry Regulatory Authority (“FINRA”) for quotation on the OTC pink sheets under the symbol “BLMB” as of July 3, 2017. FINRA announced the Company’s name change to Qrons Inc. on August 9, 2017. The new name and symbol change to “QRON” for the OTC Market was effective August 10, 2017. The Company’s common stock commenced trading on the OTCQB Venture Market on August 12, 2019.
The Company is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases, which are an enormous social and economic burden on society. The Company seeks to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The Company’s search is currently focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where its President is located and where its research to date has been conducted.
The Company’s principal executive office is located at 28-10 Jackson Avenue, Long Island City, #26N, New York 11101.
Note 2 – Summary of Significant Accounting Policies
Financial Statements: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022.
In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Fiscal year end: The Company has selected December 31 as its fiscal year end.
Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates.
Cash Equivalents: The Company considers all highly liquid investments with original maturities of 90 days or less to be cash equivalents.
Research and Development Costs: The Company charges research and development costs to expense when incurred in accordance with FASB ASC 730, Research and Development. Research and development costs were $6,820 for the three months ended March 31, 2023. Research and development costs were $8,932 for the three months ended March 31, 2022.
| 7 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 2 – Summary of Significant Accounting Policies (Continued)
Advertising and Marketing Costs: Advertising and marketing costs are expensed as incurred. The Company incurred no advertising and marketing costs during the three months ended March 31, 2023 and 2022.
Related Parties: For the purposes of these financial statements, parties are considered to be related if one party has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Company and the party are subject to common control or common significant influence. Related parties may be individuals or other entities.
Stock Based Compensation and Other Share-Based Payments: The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method of the award on grant date. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the equity instruments issued. The expense attributable to the Company’s directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company’s non-employees is recognized when vested, as described in Note 9, Stock Plan.
Fair Value of Financial Instruments
ASC 820, Fair Value Measurements, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:
Level 1 – Quoted prices in active markets for identical assets or liabilities.
Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument.
The following table provides a summary of the fair value of the Company’s derivative liabilities as of March 31, 2023 and December 31, 2022:
|
| Fair value measurements on a recurring basis |
| |||||||||
|
| Level 1 |
|
| Level 2 |
|
| Level 3 |
| |||
As of March 31, 2023: |
|
|
|
|
|
|
|
|
| |||
Liabilities |
|
|
|
|
|
|
|
|
| |||
Derivative liabilities |
| $ | - |
|
| $ | - |
|
| $ | 372,814 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2022: |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liabilities |
| $ | - |
|
| $ | - |
|
| $ | 358,775 |
|
| 8 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 2 – Summary of Significant Accounting Policies (Continued)
Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments the Company applies the Monte Carlo model to value the warrants.
Income taxes: The Company has adopted ASC 740, Income Taxes, which requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
Basic and Diluted Loss Per Share: In accordance with ASC 260, Earnings Per Share, the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common stock had been issued and if the additional shares of common stock were dilutive.
Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options.
The table below reflects the potentially dilutive securities outstanding during each reporting period:
|
| March 31, 2023 |
|
| March 31, 2022 |
| ||
Research warrants at 3% of issued and outstanding shares |
|
| 403,194 |
|
|
| 398,694 |
|
Convertible notes |
|
| 702,213 |
|
|
| 723,751 |
|
Series A preferred shares |
|
| 700 |
|
|
| 700 |
|
Stock options vested |
|
| 4,328,332 |
|
|
| 4,098,332 |
|
Stock purchase warrants |
|
| 295,000 |
|
|
| 295,000 |
|
Total |
|
| 5,729,439 |
|
|
| 5,516,477 |
|
Recently Issued Accounting Pronouncements
Adopted
In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU 2020-06 also modifies the guidance on diluted earnings per share calculations. The Company elected to adopt this guidance in the year ended December 31, 2022. There was no material effect on the Company’s operations, financial position or cash flows as a result of the adoption.
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.
| 9 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 3 – Going Concern
The Company has experienced net losses to date and has not generated revenues from operations. While the Company raised proceeds totaling $72,500 in unsecured advances from related parties in the year ended December 31, 2022 and a further $15,000 in unsecured advances from related parties during the current three months ended March 31, 2023, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the second quarter of 2023. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing, and continued support from its officers and directors. There can be no assurance that financing, whether debt or equity, will be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. In addition, if the Company is unable to obtain adequate financing from the capital markets, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations.
The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.
Covid-19 Pandemic and Other Factors
While the World Health Organization has recently declared that the COVID-19 pandemic is no longer a public health emergency of international concern and the global economy is focused on recovery, the impact of COVID-19 could continue to have an adverse impact on the Company going forward. COVID-19 caused significant disruptions to the global financial markets, which may continue to impact the Company’s ability to raise additional capital and ongoing research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during the pandemic. This resulted in our discontinuing our research at these Universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. We do not currently know the full extent of potential delays of research in the future and the ultimate impact on us and our research relationships is currently uncertain. Additional factors which may impact the Company’s ongoing operations include, but are not limited to, inflation, potential supply chain issues as a result of the aforementioned recovery from the COVID-19 pandemic, the recent war in the Ukraine and climate change. These events may have serious adverse impact on domestic and foreign economies which may impact the Company’s operations as a result of a variety of factors including the potential for difficulties obtaining additional capital. The Company is unable to predict the ongoing impact of these factors on the Company’s financial operations. There are no assurances that the Company will be able to meet its obligations, raise funds or conclude the acquisition of identified businesses.
Note 4 – Convertible Note – Related Party and Derivative Liabilities
On September 1, 2016, the Company entered into a convertible debenture agreement with Decagon LLC, doing business as CubeSquare, LLC (“CubeSquare”), of which the Company’s Chief Executive Officer is the managing partner and its President is a 25% owner of CubeSquare. The Company received proceeds of $10,000 during fiscal 2016 (“Note 1”). Note 1 bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender’s option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company’s shares are not trading on a public market and; (ii) in the event the Company’s shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
On September 29, 2017, the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018; on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019; on November 6, 2019, the Company further amended Note 1 to extend the maturity date to September 1, 2020; on October 30, 2020, the Company further amended Note 1 to extend the maturity date to September 1, 2021; and on October 7, 2021, the Company further amended Note 1 to extend the maturity date to September 1, 2022 under the same terms and conditions.
| 10 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 4 – Convertible Note – Related Party and Derivative Liabilities (Continued)
On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and was due on September 27, 2018. Interest accrues from September 27, 2017 and is payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date to September 27, 2019. On November 6, 2019, Note 2 was amended to extend the maturity date to September 27, 2020; on October 30, 2020 Note 2 was amended to extend the maturity date to September 27, 2021; and further on October 7, 2021 Note 2 was amended to extend the maturity date to September 27, 2022.
On September 27, 2022 the Board and the noteholder agreed to cancel the two convertible notes and in full satisfaction of such outstanding debt to issue a new 6% non-convertible promissory note to CubeSquare in the principal amount of $35,873 (the “New Note”), representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022.
The Company analyzed the amendment to Note 1 and Note 2 under ASC 815-10-15-83 and concluded that the conversion feature within these two convertible Notes meet the definition of a derivative. The Company estimated the fair value of the derivative at each report date using the Black-Scholes valuation model to value the derivative liability related to the variable conversion rate. There is no derivative liability associated with the New Note given the absence of a conversion feature.
The carrying value of these convertible notes is as follows:
|
| March 31, 2023 |
|
| December 31, 2022 |
| ||
Face value of certain convertible notes |
| $ | - |
|
| $ | 25,000 |
|
Convertible notes extinguish |
|
| - |
|
|
| (25,000 | ) |
Carrying value |
| $ | - |
|
| $ | - |
|
|
| For Three Months Ended March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
Interest on the convertible notes |
| $ | - |
|
| $ | 493 |
|
As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party was $0.
As a result of the application of ASC 815, the fair value of the derivative liability associated with the conversion feature is summarized as follows:
Balance at December 31, 2021 |
| $ | 73,099 |
|
Change in fair value during three months period |
|
| (20,463 | ) |
Balance at March 31, 2022 |
| $ | 52,636 |
|
The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date:
|
| Commitment Date |
|
| December 31, 2021 |
|
| March 31, 2022 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
| 101%-103 | % |
| 181%-182 | % |
| 261%~280 | % | |||
Expected term |
| 0.92 - 1 year |
|
| 0.67 - 0.74 year |
|
| 0.49 year |
| |||
Risk free interest rate |
|
| 1.33 | % |
|
| 1.06 | % |
|
| 1.06 | % |
| 11 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 5 – Convertible Note and Derivative Liabilities
(1) 8% Convertible notes with warrants issued in December 2019 and February 2020
In December 2019, we issued and sold in a private offering 8% convertible notes in the aggregate principal amount of $70,000. Such notes were due on December 31, 2021 and are convertible into shares of our common stock at a conversion price for each share of common stock equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company (to the holder or to any third party) within 30 trading days prior to the date of delivery of the applicable notice of conversion; and (c) so long as lower than (a) or (b), such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 70,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date of the notes to December 2022 upon initial maturity, and further extended the maturity date to December 2023 under the same terms and conditions during the year ended December 31, 2022.
On February 19, 2020 we issued and sold in a private offering an 8% convertible note in the principal amount of $10,000. The note is due on February 19, 2022 and is convertible into shares of common stock at a conversion price per share equal to the lesser of: (a) $0.50; (b) the lowest price at which the Company has converted any convertible security of the Company within 30 trading days prior to the date of delivery of the applicable notice of conversion; or (c) such other price as the Company and the holder may agree. In connection with the 8% convertible note issuance, we issued warrants to purchase an aggregate of 10,000 shares of common stock at an exercise price of $1.00. The Company extended the maturity date to February 2023 upon initial maturity, and further extended the maturity date to February 2024 under the same terms and conditions during the year ended December 31, 2022.
The carrying value of these convertible notes is as follows:
|
| March 31, 2023 |
|
| December 31, 2022 |
| ||
Face value of certain convertible notes |
| $ | 80,000 |
|
| $ | 80,000 |
|
Carrying value |
| $ | 80,000 |
|
| $ | 80,000 |
|
Interest expenses associated with the convertible notes are as follows:
|
| For Three Months Ended |
| |||||
|
| March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
Amortization on debt discount |
| $ | - |
|
| $ | 541 |
|
Interest on the convertible notes |
|
| 1,613 |
|
|
| 1,578 |
|
Total |
| $ | 1,613 |
|
| $ | 2,119 |
|
As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $20,882 and $19,269, respectively.
The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows:
Balance at December 31, 2022 |
| $ | 57,033 |
|
Change in fair value |
|
| 38,089 |
|
Balance at March 31, 2023 |
|
| 95,122 |
|
The convertible notes qualify for derivative accounting and bifurcation under ASC 815. As of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows:
Balance at December 31, 2021 |
| $ | 157,490 |
|
Change in fair value |
|
| (10,411 | ) |
Balance at March 31, 2022 |
| $ | 147,079 |
|
| 12 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 5 – Convertible Note and Derivative Liabilities (Continued)
The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2023 and December 31, 2022 and the commitment date:
|
| Commitment Date |
|
| December 31, 2022 |
|
| March 31, 2023 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
| 154%-173 | % |
| 194.20%-201.98 | % |
| 96.37%-98.24 | % | |||
Expected term |
| 2.10 years |
|
| 1.08 - 1.22 years |
|
| 0.83 ~ 0.97 years |
| |||
Risk free interest rate |
| 1.42-1.65 | % |
|
| 4.41 | % |
|
| 4.64 | % | |
The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date:
|
| Commitment Date |
|
| December 31, 2021 |
|
| March 31, 2022 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
| 154% ~173 | % |
| 203%~301 | % |
| 228%~245 | % | |||
Expected term |
| 2.10 years |
|
| 1.08 ~ 1.22 years |
|
| 0.83 ~ 0.97 years |
| |||
Risk free interest rate |
| 1.42 ~ 1.65 | % |
|
| 0.39 | % |
|
| 1.35 | % | |
(2) 8% Convertible note with warrants issued on June 15, 2021
On June 15, 2021, the Company entered into a note purchase agreement with Quick Capital, LLC (“Quick Capital”) pursuant to which the Company issued a twelve-month convertible promissory note in the principal amount of $115,000 for a $100,000 investment (the “Quick Note”), which included an original issuance discount of 10% and a $3,500 credit for legal and transaction costs. In connection with the Quick Note issuance, Quick Capital was also issued a five-year warrant (the “Quick Warrant”) to purchase up to an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $1.00 per share (the “Quick Warrant Shares”) subject to adjustments for dilutive issuances at lower prices.
The Quick Note is convertible into shares of common stock at a conversion price of $0.50 per share. If delivery of the conversion shares is not timely made, the Company is obligated to pay Quick Capital $2,000 for each day that the delivery is late as liquidated damages. The conversion price of the Quick Note will be reduced if the Company issues common stock or grants derivative securities for consideration at a price less than the conversion price to the amount of the consideration of such dilutive issuance. The Quick Note may not be prepaid.
The Company is subject to significant cash penalties if the Company defaults on the Quick Note or in the event shares are not issued in a timely manner when a notice of conversion is provided. If an event of default occurs, the Quick Note will become immediately due and payable in an amount equal to 150% of the then outstanding principal amount of the Quick Note plus any interest or amounts owing to Quick Capital. The default provisions are based on the type of default and include a penalty of 50% of the principal plus accrued interest due (the “Default Sum”) and a parity value of the Default Sum based on the effective conversion of the Quick Note on the date of payment of the default and the maximum stock value during the period between the default date and the payment date.
| 13 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 5 – Convertible Note and Derivative Liabilities (Continued)
(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)
The Note and accrued interest totaling $124,200 was not repaid on maturity, constituting an event of default increasing the repayment value of the note to an amount equal to 150% of the principal balance and accrued interest outstanding, or $186,300. On December 7, 2022, the Company and Quick Capital amended the Note to extend the maturity date thereof to June 15, 2023, and amended the Warrant maturity date to June 15, 2027. Further Quick Capital agreed to reduce the outstanding balance of the Note from $186,300 to $150,000 in consideration for the issuance of 150,000 shares of unregistered, restricted common stock valued at $76,350.
Details of the valuation of the 150,000 shares of common stock are set out below:
December 7, 2022: |
|
|
| |
Note Payable, original face value |
| $ | 115,000 |
|
Accrued interest and default penalty on default |
|
| 71,300 |
|
Convertible Note Payable, amended |
|
| (150,000 | ) |
Debt discount, day one, amended convertible note payable |
|
| 24,436 |
|
Derivative Liability associated with warrants |
|
| (15,416 | ) |
Change in Fair Value |
|
| 31,030 |
|
Fair value of Common stock issued |
| $ | 76,350 |
|
The unpaid balance of the Note continues to accrue interest at 8% per annum.
The Company valued the embedded default derivative liability of the Quick Note and the Quick Warrant liability, including the full ratchet reset feature, using Monte Carlo models.
The fair value of the Quick Note and Quick Warrant embedded default derivatives liability has been valued as of March 31, 2023 and December 31, 2022.
The carrying value of the Quick Note is as follows:
|
| March 31, 2023 |
|
| December 31, 2022 |
| ||
Face value of Quick Note |
| $ | 150,000 |
|
| $ | 150,000 |
|
Less: unamortized discount |
|
| (10,376 | ) |
|
| (21,753 | ) |
Carrying value |
| $ | 139,624 |
|
| $ | 128,247 |
|
Interest expenses associated with the conversion feature is as follows:
|
| For the Three Months ended |
| |||||
|
| March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
Amortization of debt discount |
| $ | 11,377 |
|
| $ | 28,750 |
|
Interest on the convertible notes |
|
| 2,959 |
|
|
| 2,268 |
|
Total |
| $ | 14,336 |
|
| $ | 31,018 |
|
| 14 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 5 – Convertible Note and Derivative Liabilities (Continued)
(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)
As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities was $3,748 and $789, respectively.
As a result of the application of ASC 815 as of March 31, 2023 and December 31, 2022, the fair value of the derivative liability associated with the conversion feature is summarized as follows:
Balance at December 31, 2022 |
| $ | 301,742 |
|
Change in fair value – convertible note |
|
| (10,740 | ) |
Change in fair value – warrants |
|
| (13,310 | ) |
Balance at March 31, 2023 |
| $ | 277,692 |
|
As a result of the application of ASC 815 as of March 31, 2022 and December 31, 2021, the fair value of the derivative liability associated with the conversion feature is summarized as follows:
Balance at December 31, 2021 |
| $ | 175,368 |
|
Change in fair value – convertible note |
|
| 14,352 |
|
Change in fair value – warrants |
|
| 182,477 |
|
Balance at March 31, 2022 |
| $ | 372,197 |
|
The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2023 and December 31, 2022 and the commitment date:
Convertible note: |
| Commitment Date |
|
| December 31, 2022 |
|
| March 31, 2023 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
|
| 307.10 | % |
|
| 119.70 | % |
|
| 119.70 | % |
Expected term |
| 1 years |
|
| 0.45 years |
|
| 0.21 years |
| |||
Risk free interest rate |
|
| 0.18 | % |
|
| 4.37 | % |
|
| 4.37 | % |
Warrants: |
| Commitment Date |
|
| December 31, 2022 |
|
| March 31, 2023 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
|
| 201.70 | % |
|
| 219.10 | % |
|
| 222.20 | % |
Expected term |
| 5 years |
|
| 4.45 years |
|
| 4.21 years |
| |||
Risk free interest rate |
|
| 0.65 | % |
|
| 4.27 | % |
|
| 4.19 | % |
| 15 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 5 – Convertible Note and Derivative Liabilities (Continued)
(2) 8% Convertible note with warrants issued on June 15, 2021 (Cont’d)
The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of March 31, 2022 and December 31, 2021 and the commitment date:
Convertible note: |
| Commitment Date |
|
| December 31, 2021 |
|
| March 31, 2022 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
|
| 307.10 | % |
|
| 215.70 | % |
|
| 336.80 | % |
Expected term |
| 1 years |
|
| 0.45 years |
|
| 0.21 years |
| |||
Risk free interest rate |
|
| 0.18 | % |
|
| 0.43 | % |
|
| 1.37 | % |
Warrants: |
| Commitment Date |
|
| December 31, 2021 |
|
| March 31, 2022 |
| |||
Expected dividends |
|
| 0 |
|
|
| 0 |
|
|
| 0 |
|
Expected volatility |
|
| 201.70 | % |
|
| 200.90 | % |
|
| 280.40 | % |
Expected term |
| 5 years |
|
| 4.45 years |
|
| 4.20 years |
| |||
Risk free interest rate |
|
| 0.65 | % |
|
| 0.82 | % |
|
| 1.350 | % |
Note 6 – Unsecured Short-Term Advance from Third Party
On June 20, 2019, the Company received $100,000 from a third party in the form of an unsecured, demand, non-interest-bearing, short-term advance to meet its operating needs. The advance remains outstanding at March 31, 2023 and December 31, 2022.
Note 7 – Related Party Transactions
(1) Demand Loan from related party
On May 1, 2019, the Company issued a promissory note (the “Note”) to CubeSquare in the principal amount of $50,000. The Company’s Chief Executive Officer is the managing partner and the Company’s President is a 25% owner of CubeSquare. The Note bears interest at the rate of 8% per annum and is due and payable by the Company upon demand from CubeSquare. The Company recorded interest expenses of $997 and $986 for the three months ended March 31, 2023 and 2022, respectively
On September 27, 2022 the Board and the related party noteholder agreed to cancel two convertible notes issued to Cubesquare and in full satisfaction of such outstanding debt to issue a new 6% promissory note (Ref: Note 4) in the principal amount of $35,873, representing the aggregate principal amount of $25,000 and the aggregate amount of any and all accrued interest in the amount of $10,873 as of September 27, 2022. The Company recorded interest expenses of $531 and $0 for the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023 and December 31, 2022, the unpaid interest balance under Accounts payable and accrued liabilities – related party in respect of the aforementioned notes was $16,763 and $15,234, respectively.
| 16 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 7 – Related Party Transactions (Continued)
(2) Advances from Related Parties
During the year ended December 31, 2019, the Company received $135,000 from Jonah Meer, its Chief Executive Officer, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $70,000 from Jonah Meer. An additional $72,500 in advances was received from Mr. Meer during the year ended December 31, 2022. An additional $15,000 in advances was received from Mr. Meer during the three months ended March 31, 2023.Mr. Meer is owed $292,500 and $277,500 in respect to these advances at March 31, 2023 and December 31, 2022, respectively.
On August 20, 2019, the Company received $50,000 from Ido Merfeld, its President, in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs. During the year ended December 31, 2020, the Company received an additional $21,000 from Ido Merfeld. There were no additional advances from Mr. Merfeld during the years ended December 31, 2022 and 2021. Mr. Merfeld is owed $71,000 in respect to these advances at March 31, 2023 and December 31, 2022.
During the year ended December 31, 2020, the Company received $10,000 from CubeSquare in the form of an unsecured, demand, non-interest-bearing, short-term advance to help meet its operating needs which amount is outstanding as of March 31, 2023 and December 31, 2022.
(3) Others
Jonah Meer, the Company’s Chief Executive Officer, made payments of $10,076 to various vendors during the three months ended March 31, 2023. The balance payable to Mr. Meer of $36,344 and $26,268 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022, respectively.
During the year ended December 31, 2019, Ido Merfeld, the Company’s President, made payments to various vendors in the aggregate amount of $1,169. The balance payable to Mr. Merfeld of $1,169 is reflected in accounts payable, related party as of March 31, 2023 and December 31, 2022.
Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement
Dartmouth College – Intellectual Property License Agreement
On October 2, 2019, the Company entered into an intellectual property license agreement (the “Intellectual Property License Agreement”) pursuant to which Dartmouth granted the Company an exclusive world-wide license under the patent application entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” in the field of human and animal health and certain additional patent rights to use and commercialize licensed products and services. The license grant includes the right of the Company to sublicense to third parties subject to the terms of the Agreement.
The Agreement provided for: (i) a $25,000 license issue fee; (ii) an annual license maintenance fee of $25,000, until the first commercial sale of a licensed product or service; (iii) an earned royalty of 2% of net sales of licensed products and services by the Company or a sublicensee; (iv) 15% of consideration received by the Company under a sublicense; and (v) beginning in the first calendar year after the first commercial sale, an annual minimum royalty payment of $500,000, $1,000,000 in the second calendar year, and $2,000,000 in the third calendar year and each year thereafter. The Company will also reimburse Dartmouth for all patent preparation, filing, maintenance and defense costs.
| 17 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 8 – Intellectual Property License Agreement and Sponsored Research Agreement (Continued)
Failure to timely make any payment due under the Agreement will result in interest charges to the Company of the lower of 10% per year or the maximum amount of interest allowable by applicable law.
The Agreement may be terminated by Dartmouth if the Company is in material breach of the Agreement which is not cured after 30 days of notice thereof or if the Company becomes insolvent. Dartmouth may terminate the Agreement if the Company challenges a Dartmouth patent or does not terminate a sublicensee that challenges a Dartmouth patent, except in response to a valid court or governmental order. The Company may terminate the Agreement at any time upon six months written notice to Dartmouth.
If the Company or any sublicensee or affiliate institutes or participates in a licensed patent challenge, the then current earned royalty rate for licensed products covered by Dartmouth patents will automatically be increased to three times the then current earned royalty rate.
On March 23, 2021, the United States Patent and Trademark Office issued U.S. Patent No. 10,954,315 to the Trustees of Dartmouth College, which is directed to mechanically interlocked, molecules-based materials for 3-D printing. The patent’s inventors are Professor Chenfeng Ke, a member of the Company’s Scientific Advisory Board and Qianming Lin, Professor Ke’s assistant. The patent grant is the culmination of the Intellectual Property License Agreement between the Company and Dartmouth with respect to an exclusive world-wide license of intellectual property related to 3D printable materials in the fields of human and animal health.
Dartmouth College – Intellectual Property License Agreement
The Company expensed $6,250 as license fees during each of the three months ended March 31, 2023 and 2022 with respect to such annual fee.
Note 9 – Stock Plan
2016 Stock Option and Stock Award
On December 14, 2016, the Board adopted the Company’s 2016 Stock Option and Stock Award Plan (the “Plan”). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Board. The Company has reserved 10 million shares for issuance under the Plan.
(a) Stock Options granted to Science Advisors and employees
On December 22, 2022, the Board granted a five-year option to purchase 325,000 shares of common stock to a scientific advisor. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date.
During the year ended December 31, 2022, various three-year stock options to purchase 145,000 shares of common stock of the Company previously granted to science advisors and employees expired unexercised.
Details of outstanding options for employees and scientific advisors at March 31, 2023 are below:
|
| Grant date |
| Vested |
|
| Unvested |
|
| Exercise price |
|
| Expiry | ||||
Scientific Advisor |
| 12/10/18 |
|
| 145,000 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/10/23 | |
|
| 12/17/19 |
|
| 33,333 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/17/23 | |
|
| 12/17/19 |
|
| 33,333 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/17/24 | |
|
| 12/10/20 |
|
| 100,000 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/10/25 | |
|
| 12//22/21 |
|
| 325,000 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/22/26 | |
|
| 12/22/22 |
|
| 325,000 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/22/27 | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Employees |
| 04/16/18 |
|
| 10,000 |
|
|
| - |
|
| $ | 2.00 |
|
| 4/16/23 | |
|
| 08/15/18 |
|
| 6,667 |
|
|
| - |
|
| $ | 2.00 |
|
| 08/15/23 | |
|
| 12/10/18 |
|
| 33,333 |
|
|
| - |
|
| $ | 2.00 |
|
| 12/10/23 | |
|
| 07/01/19 |
|
| 33,333 |
|
|
| - |
|
| $ | 2.00 |
|
| 07/01/23 | |
|
| 07/01/19 |
|
| 33,333 |
|
|
| - |
|
| $ | 2.00 |
|
| 07/01/24 | |
As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.
(b) Stock Options granted to Officers:
On December 4, 2022, a five-year stock option to purchase 600,000 shares of common stock of the Company previously granted to officers expired unexercised.
On December 22, 2022, the Board granted five-year options to purchase 325,000 shares of common stock to each of its two officers. The options have an exercise price of $2.00 per share, are immediately exercisable and were expensed on issue date.
Following are the details of stock options granted to our officers at March 31, 2023:
Name |
| Grant date |
| Exercisable |
|
| Exercise price |
|
| Expiry | |||
Jonah Meer |
| 12/10/18 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/10/2023 | |
|
| 12/17/19 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/17/24 | |
|
| 12/10/20 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/10/25 | |
|
| 12//22/21 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12//22/26 | |
|
| 12/22/22 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/22/27 | |
|
|
|
|
|
|
|
|
|
|
|
|
| |
Ido Merfeld |
| 12/10/18 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/10/2023 | |
|
| 12/17/19 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/17/24 | |
|
| 12/10/20 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/10/25 | |
|
| 12//22/21 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12//22/26 | |
|
| 12/22/22 |
|
| 325,000 |
|
| $ | 2.00 |
|
| 12/22/27 | |
As of March 31, 2023 and 2022 there was no unrecognized compensation with respect to the aforementioned stock options remaining to be recognized in future periods.
A summary of the activity for the Company’s stock options at March 31, 2023 and December 31, 2022, is as follows:
|
| March 31, 2023 |
|
| December 31, 2022 |
| ||||||||||||||||||
|
|
|
| Weighted Average Exercise |
|
| Weighted Average Remaining Contractual Life |
|
|
|
|
| Weighted Average Exercise |
|
| Weighted Average Remaining Contractual Life |
| |||||||
|
| Shares |
|
| Price |
|
| (in years) |
|
| Shares |
|
| Price |
|
| (in years) |
| ||||||
Outstanding, beginning of period |
|
| 4,328,332 |
|
| $ | 2 |
|
|
| 2.78 |
|
|
| 4,098,332 |
|
| $ | 2 |
|
|
| 3.08 |
|
Granted |
|
| - |
|
| $ | 2 |
|
|
| - |
|
|
| 975,000 |
|
| $ | 2 |
|
|
| - |
|
Exercised |
|
| - |
|
| $ | - |
|
|
| - |
|
|
| - |
|
| $ | - |
|
|
| - |
|
Canceled/forfeited |
|
| - |
|
| $ | 2 |
|
|
| - |
|
|
| (745,000 | ) |
| $ | 2 |
|
|
| - |
|
Outstanding, end of period |
|
| 4,328,332 |
|
| $ | 2 |
|
|
| 2.78 |
|
|
| 4,328,332 |
|
| $ | 2 |
|
|
| 3.03 |
|
Options exercisable, end of period |
|
| 4,328,332 |
|
| $ | 2 |
|
|
| 2.78 |
|
|
| 4,328,332 |
|
| $ | 2 |
|
|
| 3.03 |
|
Weighted average fair value of options granted |
|
|
|
|
| $ | 2 |
|
|
|
|
|
|
|
|
|
| $ | 2 |
|
|
|
|
|
| 20 |
| Table of Contents |
QRONS INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
March 31, 2023 and 2022
Note 10 – Capital Stock
Authorized:
The Company has authorized 100,000,000 shares of common stock, par value $0.0001, and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001.
Series A Preferred Stock:
The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the “Stated Value”). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company’s common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.
There were 2,000 shares of Series A Preferred Stock issued and outstanding as of March 31, 2023 and December 31, 2022.
Common Stock
In December 2022, the Company issued 150,000 shares of its common stock to Quick Capital LLC with a value of $76,350 related to a loan amendment (Note 5).
There were 13,439,789 shares of common stock issued and outstanding as of March 31, 2023 and December 31, 2022.
Common Stock Purchase Warrants
As of March 31, 2023 and December 31, 2022, the following common stock purchase warrants were outstanding:
|
| Warrants |
|
| Weighted Average Exercise Price |
| ||
Outstanding – December 31, 2021 |
|
| 295,000 |
|
| $ | 1.00 |
|
Granted |
|
| - |
|
|
| - |
|
Canceled/forfeited |
|
| - |
|
|
| - |
|
Exercised |
|
| - |
|
|
| - |
|
Outstanding – December 31, 2022 |
|
| 295,000 |
|
|
| 1.00 |
|
Granted |
|
| - |
|
|
| - |
|
Canceled/forfeited |
|
| - |
|
|
| - |
|
Exercised |
|
| - |
|
|
| - |
|
Outstanding – March 31, 2023 |
|
| 295,000 |
|
| $ | 1.00 |
|
On June 15, 2021, the Company granted a convertible noteholder a warrant to purchase 115,000 shares of common stock at an exercise price of $1.00, subject to adjustments for full ratchet resets for dilutive issuances at lower prices. (See Note 5(2) above.)
Note 11 – Subsequent Events
The Company has evaluated events for the period through the date of the issuance of these financial statements and determined that there are no additional events requiring disclosure.
| 21 |
| Table of Contents |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q contains predictions, estimates and other forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “intends,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors including the risks set forth in the section entitled “Risk Factors” in our prospectus, as filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2022, that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Report. You should read this Report with the understanding that our actual future results may be materially different from what we expect.
All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made, except as required by federal securities and any other applicable law.
The management’s discussion and analysis of our financial condition and results of operations are based upon our condensed unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The following discussion of our financial condition and results of operations should be read in conjunction with the notes to the unaudited financial statements appearing elsewhere in this Report and the Company’s audited financial statements for the fiscal year ended December 31, 2022, as filed with the SEC in its Annual Report on Form 10-K on March 31, 2023, along with the accompanying notes. As used in this Quarterly Report, the terms “we,” “us,” “our” and the “Company” means Qrons Inc.
The Company has relied primarily on its two co-founders, Jonah Meer, Chief Executive Officer, and Ido Merfeld, President, who are its sole directors to manage its day-to-day business and has outsourced professional services to third parties in an effort to maintain lower operational costs.
Messrs. Meer and Merfeld, as the holders of the Company’s issued and outstanding shares of the Company’s Class A Preferred Stock, collectively have 66 2/3% of the voting rights of the Company. Acting together, they will be able to influence the outcome of all corporate actions requiring approval of our stockholders.
Plan of Operations
We are an innovative biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. The Company’s approach is to marshal and leverage its proprietary research with developing breakthrough technologies by seeking to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases, and such other indications that may make use of our technology. The Company’s search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations and where our researchers are based.
| 22 |
| Table of Contents |
To date, the Company has collaborated with universities and scientists in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels to develop a treatment that integrates proprietary, engineer mesenchymal stem cells (“MSCs”), 3D printable implant, smart materials and a novel delivery system and has two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries, both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs.
In early 2022, the Company began collaborating with scientists at a leading University in Israel to conduct preliminary experiments to confirm that a combination of certain molecule compounds that they invented which contain immunomodulating properties when integrated with ingredients in our QS200™ product candidate may substantially improve its solubility and allow very high dosage treatments which we believe offers treatment options to diffused axonal injuries. These molecules are being tested for certain indication in various Phase II trials conducted by others.
We also believe that the improved dosage delivery may present a unique treatment option to patients who suffer from antibiotic resistant bacteria infection and Sepsis. We are looking to conduct such in vitro tests, which if successful we believe may provide an expedited pathway to human trials.
As a result of the Company's multidiscipline research effort in the field of supramolecular and polymeric materials chemistry and neuronal tissue engineering, on April 3, 2022, the Company filed a US provisional patent application for inventions of therapeutic polypseudorotaxane hydrogels, and on March 12, 2023 filed an International Patent Application at the International Bureau , thereby providing the Company with the option to, in the future, seek protection for these inventions globally. The patent application relates generally to the treatment of pathological central nervous system conditions such as traumatic injury or neurodegenerative disease and the applications of uses of hydrogels in the treatment of such conditions, as well as manufacturing techniques for such compositions,
On September 18, 2022 Ido Merfeld, our President and co-Founder was awarded his PhD in Molecular Biology and Neuroscience based on his submission of his paper entitled Mesenchymal Stem Cells integrated into Pseudopolyrotaxane hydrogels promote neuronal stem cells maturation and inhibits reactive Astrocytes and Activated Microglia after penetrating traumatic brain injury, based on the research done at Qrons.
We have not generated any revenue from the sale of products.
Results of Operations
Three Months Ended March 31, 2023 and March 31, 2022
Revenue
We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products in the near future.
Net Loss
We had a net loss of $68,458 in the three months ended March 31, 2023 compared to a net loss of $264,128 in the three months ended March 31, 2022, as follows:
|
| For the Three Months Ended |
| |||||
|
| March 31, |
| |||||
|
| 2023 |
|
| 2022 |
| ||
|
|
|
|
|
|
| ||
Net sales |
| $ | - |
|
| $ | - |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Research and development expenses |
|
| 6,820 |
|
|
| 8,932 |
|
Professional fees |
|
| 22,345 |
|
|
| 44,866 |
|
General and administrative expenses |
|
| 7,777 |
|
|
| 9,758 |
|
Total operating expenses |
|
| 36,942 |
|
|
| 63,556 |
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
| (36,942 | ) |
|
| (63,556 | ) |
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
Interest expense |
|
| (17,477 | ) |
|
| (34,617 | ) |
Change in derivative liabilities |
|
| (14,039 | ) |
|
| (165,955 | ) |
Total other income (expense) |
|
| (31,516 | ) |
|
| (200,572 | ) |
|
|
|
|
|
|
|
|
|
Net (loss) |
| $ | (68,458 | ) |
| $ | (264,128 | ) |
| 23 |
| Table of Contents |
Operating Expenses
Total operating expenses for the three months ended March 31, 2023 were $36,942 compared to total operating expenses of $63,556 for the three months ended March 31, 2022. The decrease in operating expenses during the three months ended March 31, 2023 is predominantly due to a decrease in professional fees from $44,866 for the three months ended March 31, 2022 to $22,345 for the three months ended March 31, 2022. The Company incurred additional professional fees during the three months ended March 31, 2022 as a result of the costs associated with filing a registration statement and prospectus. The Company also recorded decreases in research and development expenses from $8,932 for the three months ended March 31, 2022 to $6,820 for the three months ended March 31, 2023, and a decrease in general and administrative expenses from $9,758 during the three months ended March 31, 2022 to $7,777 for the three months ended March 31, 20223. During the three months ended March 31, 2023, the Company incurred $6,820 of research and development expenses which included technology licensing fees of $6,250 and lab supplies and expenses of $570, as compared to $8,932 in research and development fees for the three months ended March 31, 2022 which includes licensing fees of $6,250 and software license and equipment costs of $2,682.
Other Income (Expense)
Other expense in the three months ended March 31, 2023 was $31,516, which included a loss of $14,039 as a result of the change in value of derivative liabilities, and interest expense of $17,477 which is comprised of accretion of convertible notes of $11,377 and accrued interest on convertible notes payable of $6,100. Other expense in the three months ended March 31, 2022 was $200,572, which included a loss of $165,955 as a result of the change in value of derivative liabilities, and interest expense of $34,617 which is comprised of accretion of convertible notes of $29,291 and accrued interest on convertible notes payable of $5,326.
Operating Activities
Net Cash used in operating activities for the three months ended March 31, 2023 was primarily the result of net loss, offset by non-cash items including accretion of debt discount of $11,377, a loss from the change in derivative liabilities of $14,039 and changes to operating assets and liabilities, including an increase to accounts payable of $17,856 and an increase to accounts payable-related parties of $11,605. Net cash used in operating activities was $29,411 for the three months ended March 31, 2022 compared to $28,189 for the three months ended March 31, 2021. Net cash used in operating activities for the three months ended March 31, 2022 was primarily the result of net loss, offset by non-cash items, accretion of debt discount of $29,291, an increase in derivative liabilities of $165,955, and changes to operating assets and liabilities, including an increase to prepaid expenses of $2,163, an increase to accounts payable of $41,054 and an increase to accounts payable-related parties of $580.
Net Cash used in operating activities for the three months ended March 31, 2023 was the result of net loss, offset by non-cash items including accretion of debt discount of $11,377, a loss from the change in fair market value of derivative liabilities of $14,039 and changes to operating assets and liabilities, including an increase to accounts payable of $17,856 and an increase to accounts payable-related parties of $11,605. Net cash used in operating activities was $29,411 for the three months ended March 31, 2022 and was the result of net loss, offset by non-cash items including accretion of debt discount of $29,291, a loss from the change in fair market value of derivative liabilities of $165,955, and changes to operating assets and liabilities, including an increase to prepaid expenses of $2,163, an increase to accounts payable of $41,054 and an increase to accounts payable-related parties of $580.
Investing Activities
There were no investing activities during the three months ended March 31, 2023 and 2022.
Financing Activities
During the three months ended March 31, 2023 there was $15,000 of cash provided from financing activities consisting of advances from related parties. There were no financing activities during the three months ended March 31, 2022.
| 24 |
| Table of Contents |
Liquidity and Capital Resources
As of March 31, 2023, we had cash of $4,488. We are in the early stage of development and have experienced net losses to date and have not generated revenue from operations which raises substantial doubt about our ability to continue as a going concern. There are a number of conditions that we must satisfy before we will be able to commercialize potential products and generate revenue, including successful development of product candidates, which includes clinical trials, FDA approval, demonstration of effectiveness sufficient to generate commercial orders by customers, establishing production capabilities as well as effective marketing and sales capabilities for our product. We do not currently have sufficient resources to accomplish any of these conditions necessary for us to generate revenue and expect to incur increasing operating expenses. We will require substantial additional funds for operations, the service of debt and to fund our business objectives. There can be no assurance that financing, whether debt or equity, will be available to us in the amount required at any particular time or for any particular period or, if available, that it can be obtained on terms favorable to us. If additional funds are raised by the issuance of equity securities, such as through the issuance and exercise of warrants, then existing stockholders will experience dilution of their ownership interest. If additional funds are raised by the issuance of debt or other equity instruments, we may be subject to certain limitations in our operations, and issuance of such securities may have rights senior to those of the then existing stockholders. We currently have no agreements, arrangements or understandings with any person or entity to obtain funds through bank loans, lines of credit or any other sources.
We continue exploring sources of debt and equity financings as well as available grants. We are currently exploring and are in discussions for a potential strategic alliance in the biotechnology field which could advance our MSCs and neurodegenerative research. as well as treat other indications. There can be no assurance that we will reach agreement on this alliance or that the necessary financing will be available to implement the research under the alliance. In such event, we may explore other relationships with other third parties to develop or commercialize products or technologies that we have not previously sought to develop or commercialize, decide to exit our existing business, cease operations altogether or pursue an acquisition of our company. However, without additional financing, we do not believe our resources will be sufficient to meet our operating and capital needs beyond the second quarter of 2023.
Offering
The Company filed a registration statement on Form S-1 with the SEC on January 11, 2022, to offer and sell up to 2,500,000 shares of common stock in a self-underwritten primary offering at a fixed price of $0.70 per share which was declared effective on January 11, 2022. To date, no shares have been sold and there can be no assurance that the Company will be successful in selling any of the shares being offered.
Going Concern
Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. Our report from our independent registered public accounting firm for the fiscal year ended December 31, 2022 includes an explanatory paragraph stating the Company has recurring losses and limited operations which raise substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.
| 25 |
| Table of Contents |
COVID-19 Pandemic and other factors
While the World Health Organization has recently declared that the COVID-19 pandemic is no longer a public health emergency of international concern and the global economy is focused on recovery, the impact of COVID-19 could continue to have an adverse impact on the Company going forward. COVID-19 caused significant disruptions to the global financial markets, which may continue to impact the Company’s ability to raise additional capital and ongoing research and development of our product candidates. Research facilities at Dartmouth were subject to closures as well as laboratories at Ariel in Israel during the pandemic. This resulted in our discontinuing our research at these Universities and was part of our decision to adjust our research to be collaborative and to seek aligning with third parties to advance our expanded goals. We do not currently know the full extent of potential delays of research in the future and the ultimate impact on us and our research relationships is currently uncertain. Additional factors which may impact the Company’s ongoing operations include, but are not limited to, inflation, potential supply chain issues as a result of the aforementioned recovery from the COVID-19 pandemic, the recent war in the Ukraine and climate change. These events may have serious adverse impact on domestic and foreign economies which may impact the Company’s operations as a result of a variety of factors including the potential for difficulties obtaining additional capital. The Company is unable to predict the ongoing impact of these factors on the Company’s financial operations. There are no assurances that the Company will be able to meet its obligations, raise funds or conclude the acquisition of identified businesses.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements.
Critical Accounting Estimates
The financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, costs and expenses and related disclosures. We base our estimates on historical experience, as appropriate, and on various other assumptions that we believe are reasonable under the circumstances. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly, actual results could differ significantly from the estimates made by our management. We evaluate our estimates and assumptions on an ongoing basis. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Our significant accounting policies are more fully discussed in Note 2 to our unaudited condensed financial statements contained herein.
Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The estimates used for, but not limited to, the fair value of financial instruments, stock based compensation and warrants could be impacted. We have assessed the impact and are not aware of any specific events or circumstances that required an update to our estimates and assumptions or materially affected the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.
Estimates
Stock Based Compensation and Other Share-Based Payments: The Company records stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation, using the fair value method of the award on grant date. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the equity instruments issued. The expense attributable to the Company’s directors is recognized over the period the amounts are earned and vested, and the expense attributable to the Company’s non-employees is recognized when vested.
Warrants: The Company accounts for common stock warrants in accordance with applicable accounting guidance provided in ASC 815 Derivatives and Hedging, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. For warrants classified as equity instruments the Company applies the Black Scholes model and expenses the fair value as financing costs. For warrants classified as derivative financial instruments the Company applies the Monte Carlo model to value the warrants.
Recent Accounting Pronouncements
Adopted
In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU 2020-06 also modifies the guidance on diluted earnings per share calculations. The Company elected to adopt this guidance in the year ended December 31, 2022. There was no material effect on the Company’s operations, financial position or cash flows as a result of the adoption.
There were various accounting standards and interpretations issued recently, none of which are expected to have a material effect on the Company’s operations, financial position or cash flows.
| 26 |
| Table of Contents |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company and are not required to provide this information.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, as of March 31, 2023, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer and principal financial officer have concluded that, based on the material weaknesses discussed below, our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act were recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Act Commission’s rules and forms and that our disclosure controls are not effectively designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our internal controls and procedures are not effective for the following reasons: (i) there is an inadequate segregation of duties consistent with control objectives as management is comprised of only two persons, one of which is the Company’s principal executive officer and principal financial officer and, (ii) the Company does not have a formal audit committee with a financial expert, and thus the Company lacks the board oversight role within the financial reporting process.
In order to mitigate the foregoing material weakness, we have engaged an outside accounting consultant with significant experience in the preparation of financial statements in conformity with GAAP to assist us in the preparation of our financial statements to ensure that these financial statements are prepared in conformity with GAAP. We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate.
We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties. Management will continue to reassess this matter to determine whether improvement in segregation of duty is feasible. In addition, we would need to expand our board to include independent members.
Going forward, we intend to evaluate our processes and procedures and, where practicable and resources permit, implement changes in order to have more effective controls over financial reporting.
Changes in Internal Control over Financial Reporting
During the period covered by this report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 27 |
| Table of Contents |
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.
ITEM 1A. RISK FACTORS
The Company is a smaller reporting company and is not required to provide this information.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of equity securities during the period covered by this Report that were not registered under the Securities Act and were not previously reported in a Current Report on Form 8-K filed by the Company.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable
ITEM 5. OTHER INFORMATION
None
| 28 |
| Table of Contents |
ITEM 6. EXHIBITS
Exhibit Number |
| Exhibit |
| ||
| ||
101.INS |
| XBRL INSTANCE DOCUMENT |
101.SCH |
| XBRL TAXONOMY EXTENSION SCHEMA |
101.CAL |
| XBRL TAXONOMY EXTENSION CALCULATION LINKBASE |
101.DEF |
| XBRL TAXONOMY EXTENSION DEFINITION LINKBASE |
101.LAB |
| XBRL TAXONOMY EXTENSION LABEL LINKBASE |
101.PRE |
| XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE |
| 29 |
| Table of Contents |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| QRONS INC. |
| |
|
|
|
|
Date: May 15, 2023 | By: | /s/ Jonah Meer |
|
|
| Jonah Meer |
|
|
| Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) |
|
| 30 |
1 Year Qrons (QB) Chart |
1 Month Qrons (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
